Cargando…

Staging of oesophageal cancer

Diagnosis of oesophageal cancer is usually made at endoscopic biopsy. Imaging is used to stage the tumour, assess response to therapy, and detect complications of therapy and recurrence. For therapy planning, differentiation of resectable (T1–T3, N0, localised N1) versus irresectable disease (T4, ex...

Descripción completa

Detalles Bibliográficos
Autor principal: Diederich, Stefan
Formato: Texto
Lenguaje:English
Publicado: e-Med 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727964/
https://www.ncbi.nlm.nih.gov/pubmed/17921083
http://dx.doi.org/10.1102/1470-7330.2007.9003
_version_ 1782170714983366656
author Diederich, Stefan
author_facet Diederich, Stefan
author_sort Diederich, Stefan
collection PubMed
description Diagnosis of oesophageal cancer is usually made at endoscopic biopsy. Imaging is used to stage the tumour, assess response to therapy, and detect complications of therapy and recurrence. For therapy planning, differentiation of resectable (T1–T3, N0, localised N1) versus irresectable disease (T4, extensive N1, M1) is important. Endoscopic ultrasound (EUS) is the method of choice for diagnosing T1–T3 stages, and N0 versus N1, including endoscopic ultrasound (EUS)-guided fine-needle aspiration. Computed tomography (CT) or magnetic resonance imaging (MRI) are used to demonstrate infiltration of adjacent structures, distant lymphadenopathy and distant metastases, however, positron emission tomography (PET) and PET-CT are superior in this respect. If imaging suggests irresectable disease, histologic confirmation may be required in order not to prevent curative resection in false positive findings.
format Text
id pubmed-2727964
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher e-Med
record_format MEDLINE/PubMed
spelling pubmed-27279642009-10-01 Staging of oesophageal cancer Diederich, Stefan Cancer Imaging Article Diagnosis of oesophageal cancer is usually made at endoscopic biopsy. Imaging is used to stage the tumour, assess response to therapy, and detect complications of therapy and recurrence. For therapy planning, differentiation of resectable (T1–T3, N0, localised N1) versus irresectable disease (T4, extensive N1, M1) is important. Endoscopic ultrasound (EUS) is the method of choice for diagnosing T1–T3 stages, and N0 versus N1, including endoscopic ultrasound (EUS)-guided fine-needle aspiration. Computed tomography (CT) or magnetic resonance imaging (MRI) are used to demonstrate infiltration of adjacent structures, distant lymphadenopathy and distant metastases, however, positron emission tomography (PET) and PET-CT are superior in this respect. If imaging suggests irresectable disease, histologic confirmation may be required in order not to prevent curative resection in false positive findings. e-Med 2007-10-01 /pmc/articles/PMC2727964/ /pubmed/17921083 http://dx.doi.org/10.1102/1470-7330.2007.9003 Text en © 2007 International Cancer Imaging Society
spellingShingle Article
Diederich, Stefan
Staging of oesophageal cancer
title Staging of oesophageal cancer
title_full Staging of oesophageal cancer
title_fullStr Staging of oesophageal cancer
title_full_unstemmed Staging of oesophageal cancer
title_short Staging of oesophageal cancer
title_sort staging of oesophageal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727964/
https://www.ncbi.nlm.nih.gov/pubmed/17921083
http://dx.doi.org/10.1102/1470-7330.2007.9003
work_keys_str_mv AT diederichstefan stagingofoesophagealcancer